Tralokinumab plus optional use of TCS or TCI in adults with moderate to severe AD was associated with stable disease control for up to 4 years.

New real-world evidence highlights lebrikizumab’s effectiveness and safety in atopic dermatitis. Discover how patients ...

Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease mechanisms including IL-13 and therefore makes targeting IL-13 with lebrikizumab a ...

Please provide your email address to receive an email when new articles are posted on . Eczema, or atopic dermatitis (AD), is an increasingly prevalent chronic inflammatory skin condition that affects ...

Please provide your email address to receive an email when new articles are posted on . Percentages of patients with at least one atopic comorbidity ranged from 69.9% to 75.4%. Percentages of patients ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...

Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.

Credit: Lilly The approval of Ebglyss, an interleukin-13 antagonist, was supported by data from 3 clinical trials. Ebglyss can be used with or without topical corticosteroids. The Food and Drug ...

A 28-year-old woman presented to her primary care provider with the chief report of persistent itch associated with atopic dermatitis (AD), with itch severity worst on her hands bilaterally. AD was ...

HealthDay News — Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study published online Nov. 27 in Nutrients.

Nemolizumab showed statistically significant improvements in the coprimary endpoints of IGA success and EASI-75 compared with placebo. The Food and Drug Administration (FDA) has approved Nemluvio ® ...